Effects of Kava (Kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes

Phytomedicine

Volumn 11, Issue 4, 2004, Pages 285-294

  Zou, L ^a   Henderson, Gary L ^a   Harkey, M R ^a   Sakai, Y ^b   Li, A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Phase 1 Molecular Toxicology   (United States)

Author keywords

Cytotoxicity; Hepatocytes; Hepatotoxicity; Kava; P450 inhibition; Piper methysticum

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHLORZOXAZONE; COMPLEMENTARY DNA; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DESMETHOXYYANGONIN; DEXTROMETHORPHAN; FURAFYLLINE; ISOPROTEIN; KAVA; LACTONE DERIVATIVE; MEPHENYTOIN; METHYSTICIN; OMEPRAZOLE; PHENACETIN; PLANT EXTRACT; QUINIDINE; SULFAPHENAZOLE; TESTOSTERONE; TOLBUTAMIDE; TRANYLCYPROMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YANGONIN;

ARTICLE; CATALYSIS; CELL VIABILITY; CRYOPRESERVATION; CYTOTOXICITY; DRUG CROSS REACTIVITY; DRUG POTENCY; DRUG PURIFICATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INHIBITION KINETICS; LIVER CELL; LIVER TOXICITY; MEDIAN EFFECTIVE CONCENTRATION; MEDICINAL PLANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

PIPER METHYSTICUM;

EID: 2442706282     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1078/0944711041495263     Document Type: Article

References (40)

1. Almeida JC, Grimsley EW (1996) Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med 125: 940-941
2. Blumenthal M (2001) Herb sales down 15 percent in main-stream market. Herbalgram 51: 69
3. Blumenthal M, Goldberg A, Brinckmann J (2000) Herbal Medicine: Expanded Commission E Monographs, pp 223, Integrative Medicine Communications, Newton, MA
4. Cantor C (1997) Kava and alcohol. Med J Aust 167: 560
5. Cass H, McNally T (1998) Kava: nature's answer to stress, anxiety, and insomnia. Prima Health, Rocklin, CA
6. Crespi C (1999) Higher-throughput screening with human cytochromes P450. Current Opin Drug Disc Dev 2: 15-19
7. Crespi CL, Penman BW (1997) Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Advan Pharmacol 43: 171-188
8. Cupp MJ (1999) Herbal remedies: adverse effects and drug interactions. Am Fam Physician 59: 1239-1245
9. D'Arcy PF (1995) Nutrient-drug interactions. Adverse Drug React Toxicol Rev 14: 233-254
10. Dierks, EA, Stams KR, Lim HK, Cornelius G, Zhang, H, Ball SE (2001) A method for the simultaneous evaluation of the activities of seven major human drug metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispo 29(1): 23-29
11. Easterbrook J, Lu C, Sakai Y, Li AP (2001) Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispo 29: 141-144
12. Escher M, Desmeules J, Giostra E, Mentha G (2001) Hepatitis associated with Kava, a herbal remedy for anxiety. Br Med J 322: 139
13. Fuhr U (1998) Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Safety 18: 251-272
14. Gold JL, Laxer DA, Dergal JM, Lanctot KL, Rochon PA (2001) Herbal-drug therapy interactions: a focus on dementia. Curr Opin Clin Nutr Metab Care 4: 29-34
15. Henderson GL, Harkey MR, Gershwin, ME, Hackman, RM, Stern JS, Stresser DM (1999) Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 65: 209-214
16. Izzo AA, Ernst E (2001) Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 61: 2163-2175
17. Janetzky K, Morreale AP (1997) Probable interaction between warfarin and ginseng. Am J Health-System Pharm 54: 692-693
18. Kilham C (1996) Kava: medicine hunting in paradise. Park Street Press, Rochester, Vt
19. Kraft M, Spahn TW, Menzel J, Senninger N, Dietl KH, Herbst H, Domschke W, Lerch MM (2001) Fulminant liver failure after administration of the herbal antidepressant Kava-Kava. Dtsch Med Wochenschr 126: 970-972
20. Kubatova A, Miller DJ, Hawthorne SB (2001) Comparison of subcritical water and organic solvents for extracting kava lactones from kava root. J Chromatogr A 923: 187-194
21. Lebot V, Levesque J (1996) Genetic control of kavalactone chemotypes in Piper methysticum cultivars. Phytochemistry 43: 397-403
22. Lebot V, Merlin MD, Lindstrom L (1997) Kava - the Pacific elixir: the definitive guide to its ethnobotany, history, and chemistry. Healing Arts Press, Rochester, VT
23. Lewis CW, Frongillo EA, Jr., Roe DA (1995) Drug-nutrient interactions in three long-term-care facilities. J Am Dietetic Asso 95: 309-315
24. Li AP (1997) Primary hepatocyte cultures as an in vitro experimental model for the evaluation of pharmacokinetic drug-drug interactions., in: Drug-Drug Interactions: Scientific and Regulatory Perspectives (Li AP ed), 103-130, Academic Press, San Diego
25. Li AP, Lu C, Brendt JA, Pham C, Fackett A, Ruegg CE, Silber PA (1999) Cryopreserved human hepatocytes. Characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem-Biol Interact 121: 17-35
26. Lindenberg D, Pitule-Schodel H (1990) D,L-kavain in comparison with oxazepam in anxiety disorders. A doubleblind study of clinical effectiveness. Fortschr Med 108: 49-50, 53-44
27. Malsch U, Kieser M (2001) Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. Psychopharmacol (Berl) 157: 277-283
28. Mathiews LM, Etheridge AM, Black, SR (2002) Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab Dispo 30: 1153-1157
29. Miller LG (1998) Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 158: 2200-2211
30. Petty RD, Sutherland LA, Hunter EM, Cree IA (1995) Comparison of MTT and ATP-bases assays for the measurement of viable cell number. J Biolumin Chemilumin 10: 29-34
31. Pittler MH, Ernst E (2000) Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharmacol 20:84-89
32. Raucy JL (2003) Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispo 31: 533-539.
33. Russmann S, Escher M, Stoller R, Lauterburg BH (2001a) Hepatotoxicity of kava kava (Piper methysticum) containing herbal drugs. Recent cases in Switzerland and investigations regarding the mechanism. J Exp Klin Pharmakol Toxicol 363: S40
34. Russmann S, Lauterburg BH, Helbling A (2001b) Kava hepatotoxicity. Ann Intern Med 135: 68-69
35. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, Watkins PB (1997) Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 25: 1228-1233
36. Strahl S, Ehret V, Dahm HH, Maier KP (1998) Necrotizing hepatitis after taking herbal remedies. Dtsch Med Wochenschr 123: 1410-1414
37. Warnecke G (1991) Psychosomatic dysfunctions in the female climacteric. Clinical effectiveness and tolerance of Kava Extract WS 1490. Fortschr Med 109: 119-122
38. Williamson EM (2001) Synergy and other interactions in phytomedicines. Phytomedicine 8: 401-409
39. Zou L, Harkey MR, Henderson GL (2002a) Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 71: 1579-1589
40. Zou L, Harkey MR, Henderson GL (2002b) Intrinsic fluorescence and quenching as possible interferences in in-vitro drug-drug interaction studies. Phytomedicine 9: 263-269